Related by context. All words. (Click for frequent words.) 70 ACR# response 67 DAS# [002] 66 ACR# ACR# 66 ACR# responses 65 CIMZIA TM 64 Index CDAI 64 plus methotrexate 64 Crohn Disease Activity 64 undetectable HCV RNA 63 complete cytogenetic 63 CDAI 63 #mg BID [001] 63 Montgomery Asberg Depression 63 ACR Pedi 63 DAS# remission 63 abdominal pain abdominal discomfort 62 ACTEMRA TM 62 mucosal healing 62 Psoriasis Area 62 HAQ DI 62 achieved ACR# 61 sUA 61 mg QD 61 tocilizumab 61 Rating Scale MADRS 61 CCyR 61 Timed Walk 61 plus MTX 60 evaluable subjects 60 Disease Activity 60 placebo p = 60 RECIST Response Evaluation Criteria 60 virologic response 60 IPSS 60 CSBM 60 achieved statistical significance 60 spontaneous bowel movements 60 CDAI score 60 sustained virologic response 60 secondary endpoint 60 8mg/kg 59 CRp 59 adalimumab 59 ADCS CGIC 59 Solid Tumors criteria 59 DAS# CRP 59 CR nPR 59 etanercept 59 MADRS 59 EDSS score 59 MADRS score 59 Montgomery Åsberg Depression 59 methotrexate monotherapy 59 clinically meaningful improvement 59 seropositive patients 59 complete cytogenetic response 59 chlorambucil 59 HDRS 59 cytogenetic response 58 EDSS 58 liver histology 58 mcg BID 58 Ishak fibrosis score 58 Scale EDSS 58 Rheumatology ACR 58 Free Survival PFS 58 Expanded Disability Status 58 undetectable HBV DNA 58 placebo p 58 serologically active patients 58 HBeAg negative patients 58 achieved PASI 58 plus dexamethasone 58 XIENCE V PROMUS Stent 58 NIHSS 58 primary efficacy endpoint 58 Unified Parkinson Disease 58 apremilast 58 HBeAg seroconversion 58 ULORIC 58 mg BID 58 prespecified 58 noninferiority 57 primary endpoint 57 SVR# 57 TNSS 57 bortezomib refractory 57 evaluable 57 YMRS 57 Severity Index PASI 57 sustained virological response 57 binary restenosis 57 ACTEMRA 57 somatostatin analog 57 desvenlafaxine succinate 57 clinical endpoints 57 free survival PFS 57 radiographic progression 57 CIMZIA ™ 57 mTSS 57 nodular partial response 57 CIMZIA TM certolizumab pegol 57 placebo dexamethasone 57 Score DAS# 57 clinically meaningful improvements 57 enthesitis 57 oxycodone CR 57 progression TTP 57 prospectively defined 57 definite stent thrombosis 57 peginterferon alfa 2a 57 mcg QD 57 PsA 57 comparator arm 57 WOMAC 57 SELENA SLEDAI score 56 mRCC 56 PASI scores 56 certolizumab 56 icatibant 56 achieving PASI 56 PANSS total 56 Secondary endpoints 56 placebo fluoxetine 56 macroalbuminuria 56 Primary endpoints 56 active comparator 56 biochemical relapse 56 Hb A1C 56 ADAS cog 56 undetectable viral load 56 morphometric vertebral fractures 56 LEXIVA r 56 lumbar spine BMD 56 GERD symptom 56 lopinavir r arm 56 mg dose 56 Flu Cy 56 tapentadol ER 56 seroprotection 56 endoscopic remission 56 urinary N telopeptide 56 Alzheimer Disease Assessment 56 Thrombolysis 56 efficacy endpoint 56 rapid virological response 56 HbA 1c 56 clinically meaningful 56 mg/m2 dose 56 median PFS 56 Response Evaluation Criteria 56 achieved sustained virological 56 Lupuzor ™ 56 pCR 56 secondary efficacy endpoint 56 alteplase 56 plus prednisone 56 nasal symptom 56 timepoint 56 IBDQ 56 lacosamide 56 corticosteroid dose 56 budesonide pMDI 56 FOLPI 55 HBeAg positive patients 55 recurrent glioblastoma multiforme 55 uncorrected visual acuity 55 UPDRS 55 CR CRu 55 viral kinetics 55 Secondary endpoints included 55 certolizumab pegol 55 secondary efficacy endpoints 55 mg ustekinumab 55 nonresponders 55 PANSS 55 annualized relapse 55 serum urate 55 BENICAR 55 demonstrated clinically meaningful 55 4mg/kg 55 ALND 55 serum HBV DNA 55 cEVR 55 International Prostate Symptom 55 Secondary efficacy endpoints 55 Score DAS 55 adalimumab Humira 55 serum phosphorus 55 achieved CCyR 55 demonstrated statistically significant 55 LVEF 55 copies mL 55 Solid Tumors RECIST 55 primary patency 55 BENICAR HCT 55 Y BOCS 55 locoregional disease 55 Doxil ® 55 microbiological eradication 55 mg TID 55 tipranavir r 55 Pegasys ® 55 hemoglobin A1c levels 55 HbA1c levels 55 lopinavir r 55 CNS LS 55 -#.# mg dL [002] 55 Durezol 55 NIS LL 55 RAPAFLO R 55 Traficet EN 55 NLX P# 55 secondary endpoints 55 RECIST criteria 55 MCyR 55 recurrent GBM 55 #mg/day [001] 55 VELCADE melphalan 55 Score TOS 55 FOLFOX4 55 baminercept 55 NYHA functional class 55 Elitek 55 #.#/#.# mmHg [001] 55 mg kg dose 55 Operative mortality 55 evaluable patients 55 HAMD 54 alanine aminotransferase ALT 54 Brief Psychiatric 54 p = #.# [002] 54 mg BID dose 54 ADAS Cog 54 tolvaptan 54 infliximab 54 low dose cytarabine 54 achieved sustained virologic 54 symptom severity 54 HbA1c 54 glycated hemoglobin levels 54 dapagliflozin plus 54 ximelagatran 54 graft dysfunction 54 irbesartan 54 HbA 1c levels 54 Pegasys plus Copegus 54 Solid Tumors 54 RGT arm 54 partial remissions 54 log# reduction 54 remission CR 54 gout flares 54 p = #.# [004] 54 receiving golimumab 54 fondaparinux 54 serum phosphate levels 54 Visual Analog Scale 54 -#.# log# 54 HbA1C 54 response CCyR 54 virological response 54 methotrexate MTX 54 #mg BID [003] 54 peginterferon 54 ARCOXIA 54 undetectable virus HCV 54 mg kg belimumab 54 IU mL 54 null responders 54 #.#mg/dL 54 briakinumab 54 SSRI citalopram 54 NIH CPSI 54 P = .# 54 pegylated interferon alfa 54 Hamilton Anxiety Scale 54 DAPT 54 placebo 54 Sustained virologic response 54 metastatic renal cell carcinoma 54 #mg/day [002] 54 HBeAg 54 eosinophilic asthma 54 Health Assessment Questionnaire 54 detectable HCV RNA 54 relapsed MM 54 FOLFOX6 54 primary efficacy endpoints 54 fibrinolysis 54 prednisone prednisolone plus 54 mcg Albuferon 54 tipranavir ritonavir 54 ribavirin RBV 54 antipsychotic efficacy 54 stage IIIb IV 54 PEG IFN 54 Fibromyalgia Impact Questionnaire 54 fasting plasma glucose FPG 54 Negative Syndrome 53 APTIVUS r 53 virologic failure 53 monotherapy 53 PSADT 53 XIENCE V demonstrated 53 mcg albinterferon alfa 2b 53 PSA nadir 53 nilotinib 53 schizophrenia CIAS 53 MoxDuo TM IR 53 rapid virologic response 53 MACCE 53 tiotropium 53 chemoradiotherapy 53 mg qd 53 Kaplan Meier analysis 53 chemoradiation therapy 53 RoACTEMRA 53 ARB telmisartan 53 BARACLUDE r 53 refractory AML 53 log# IU mL 53 RECIST 53 Secondary endpoints include 53 complete remissions 53 timepoints 53 Engerix B 53 Visual Analogue Scale VAS 53 lymphocytosis 53 ejection fractions 53 doripenem 53 T2DM 53 fluticasone salmeterol 53 adjunctive placebo 53 carotid intima media 53 -#.# mg dL [001] 53 saline placebo 53 bleeding pallor 53 DMARD 53 galiximab 53 REYATAZ r 53 tirofiban 53 chronic angina 53 amoxicillin clavulanate 53 PREZISTA r 53 CsA 53 biologic therapy 53 follicular NHL 53 NMIBC 53 baseline HbA1c 53 posaconazole 53 adefovir treated 53 non menstrual pelvic 53 teriflunomide 53 splenectomized patients 53 IRLS 53 STRIDE PD 53 nonoperative treatment 53 INC# 53 oral diclofenac 53 FluCAM 53 TLUS 53 #mg QD [001] 53 glycated hemoglobin 53 IBS C 53 pain palliation 53 platelet reactivity 53 Scale EDSS score 53 BARACLUDE ® 53 low dose Iluvien 53 invasive aspergillosis 53 PREZISTA r arm 53 primary endpoints 53 tipranavir 53 ARIXTRA 53 CSBMs 53 ACZ# 53 lamivudine refractory patients 53 everolimus eluting stents 53 pegylated interferon alpha 53 FOLFOX 53 alvimopan 53 clodronate 53 T#I [002] 53 #mg QD [002] 53 mL/min/#.# m 2 53 hepatitis C genotype 53 Median PFS 53 TAXUS p value 53 achieve sustained virologic 53 NATRECOR R 53 paliperidone ER 53 nicardipine 53 CI -#.# 53 SCr 53 serum phosphate 53 ATACAND 53 plasma uric acid 53 lispro 53 HAM D# scores 53 Severity MSCS score 53 CTEPH 53 AGILECT ® 53 Pred Forte 53 posttreatment 53 XIENCE V vs. 53 sulfasalazine 53 HOMA IR 53 pT2 53 Fidaxomicin 53 belimumab 53 Folfox 53 vidofludimus 53 postprocedure 53 cisplatin vinorelbine 53 p ≤ 53 PCWP 53 active ankylosing spondylitis 53 rolofylline 53 Etanercept 53 diameter stenosis 53 fasting plasma glucose 53 R0 resection 52 mITT population 52 PEG interferon 52 BPH Symptom Score 52 mcg kg 52 transaminases 52 hypogonadal men 52 Pain Intensity 52 Ankylosing Spondylitis 52 p = .# [001] 52 patients evaluable 52 Rating Scale UPDRS 52 XELOX 52 INCB# [003] 52 IRLS score 52 glycoprotein IIb IIIa inhibitors 52 hemagglutination inhibition 52 UPDRS motor 52 mRS 52 prespecified secondary 52 IFN α 52 ipsilateral stroke 52 hemoglobin A1c HbA1c 52 decitabine 52 adjunctive ABILIFY 52 glatiramer acetate 52 systemic embolism 52 knee osteoarthritis OA 52 ug kg 52 Torisel 52 opioid induced constipation OIC 52 composite endpoint 52 alanine aminotransferase 52 rosuvastatin #mg 52 anemia hemoglobin 52 Index CDAI score 52 Ocrelizumab 52 SSRI SNRI 52 peginterferon alfa 2b 52 Welchol 52 cytogenetic responses 52 retinal thickness 52 tolterodine ER 52 solifenacin 52 log# copies mL 52 BCVA 52 Golimumab 52 μmol L 52 mcg dose 52 confirmed CCyR 52 rFVIIa 52 titrated glipizide 52 nonoperative 52 Aptivus ® 52 leukemia AML 52 xanthine oxidase inhibitor 52 p = NS 52 DLQI 52 % CI #.#-#.# [003] 52 IL 1ß 52 urate lowering therapy 52 brivaracetam 52 FDA defined valvulopathy 52 Acute Coronary Syndromes ACS 52 plasma HCV RNA 52 Rapid Virological Response 52 relapsed refractory multiple myeloma 52 rimonabant #mg/day 52 mCRPC 52 nucleoside naive patients 52 IR prednisone 52 golimumab CNTO 52 pharmacodynamic 52 nausea photophobia 52 postdose 52 aromatase inhibitor therapy 52 prospective multicenter randomized 52 Cethromycin 52 plus ribavirin 52 serum clusterin levels 52 subcutaneously administered 52 Virulizin ® 52 allopurinol 52 ALVESCO 52 prospectively stratified 52 severe exacerbations 52 Oral Fingolimod 52 MabCampath 52 Lucentis monotherapy 52 metastatic CRC 52 LHON 52 Lamictal XR 52 infliximab monotherapy 52 sirolimus stent 52 Lubiprostone 52 fosbretabulin 52 GAMMAGARD 52 R# #mg BID 52 unfractionated heparin UFH 52 5-FU/LV 52 metastatic hormone refractory 52 regorafenib 52 nondiabetic patients 52 APTIVUS R 52 atheroma volume 52 SEROQUEL XR 52 oral rivaroxaban 52 SGRQ 52 PEGylated anti 52 inflammatory lesions 52 Raptiva r 52 juvenile idiopathic arthritis 52 NATRECOR ® 52 oral allopurinol 52 TEAEs 52 methacholine challenge 52 febuxostat 52 EMBLEM TM 52 abiraterone acetate 52 salmeterol fluticasone 52 diabetic neuropathic pain 52 triamcinolone 52 neoadjuvant chemotherapy 52 log# 52 antibody titer 52 ASCT 52 STN stimulation 52 μg dose 52 WOMAC TM 52 statistically significant p = 52 Campath alemtuzumab 52 erythrocyte sedimentation rate 52 relapsing multiple sclerosis 52 Solid Tumours 52 riociguat 52 virologic response EVR 52 reduce serum phosphate 52 -#.# log# copies mL 52 baseline A1C 52 femoral neck BMD 52 #:# randomization 52 dasatinib 52 glimepiride 52 odanacatib 52 lumiliximab 52 ARCALYST ® 52 Peg IFN 52 IOP lowering 52 SBMs 52 oral FTY# 52 beta 1a 52 diabetic gastroparesis 52 IRESSA 52 plus gemcitabine 52 XGEVA 52 death reinfarction 52 Cmax 52 RLAI 52 sham injections 52 weekly CSBMs 52 Visual acuity 52 MACUGEN 52 L PPDS 52 Retisert TM 52 Virologic 52 histologically confirmed 52 Fludara 52 statistically significant p 51 Systemic Sclerosis 51 Aflibercept 51 mesalamine granules 51 receiving highly emetogenic 51 GSK# [001] 51 6R BH4 51 surrogate endpoint 51 A1c levels 51 Events MACE 51 STELARA 51 logMAR 51 minimally symptomatic 51 ETDRS 51 biliary tract cancer 51 heavily pretreated 51 #mg dose [002] 51 visilizumab 51 TIMI 51 daunorubicin 51 pegylated interferon alfa 2b 51 postmenopausal osteoporotic women 51 Capesaris 51 TroVax ® 51 mm Stent 51 pharmacokinetic equivalence 51 T2 lesions 51 mCRC patients 51 #mg BID [002] 51 crossclamp 51 leukocyte count 51 REVIVE Diabetes 51 AVODART 51 GEM OS1 51 intermittent claudication 51 oblimersen 51 cabazitaxel 51 periprocedural MI 51 hip BMD 51 humanized interleukin 6 51 MAGE A3 ASCI 51 RAPTIVA 51 metastatic malignant melanoma 51 INVEGA ® 51 polyarticular 51 Cimzia ® certolizumab pegol 51 peg interferon 51 mg doses 51 calcineurin inhibitor 51 KRAS mutations occur 51 ponatinib 51 PEGylated Fab fragment 51 Pemetrexed 51 PAOD 51 LPV r 51 squamous histology 51 pramipexole 51 mg Lucentis 51 Median progression 51 PASI 51 subscale scores 51 ZOLINZA 51 creatinine clearance 51 mTOR inhibitor 51 Teriflunomide 51 arterial thickening 51 chloride secretion 51 Non inferiority 51 HBeAg negative 51 preoperatively 51 EURIDIS 51 primary generalized tonic 51 prior chemotherapy regimens 51 IFN alfa 51 cinacalcet 51 intact parathyroid hormone 51 stage IIIB 51 TIMP 1 51 non constipation irritable 51 x ULN 51 phase IIb study 51 COZAAR 51 mitoxantrone plus 51 OAB symptoms 51 renal allograft 51 doxazosin 51 SEROQUEL 51 pg mL 51 Global Impression CGI 51 RRMS patients 51 analgesic efficacy 51 microalbuminuria 51 abatacept 51 Q#IR 51 metastatic RCC 51 tumor shrinkage 51 citalopram 51 bosutinib 51 histologic 51 ALT normalization 51 tamsulosin 51 dosing cohort 51 tumor progression TTP 51 pegylated alpha interferon 51 noninferior 51 QD dosing 51 octreotide LAR 51 systolic dysfunction 51 biochemical recurrence 51 piperacillin tazobactam 51 clobazam 51 lung metastases 51 carotid stenosis 51 CANCIDAS 51 EDSS scores 51 GORE VIABAHN Endoprosthesis 51 cell lymphoma CTCL 51 left ventricular diastolic 51 gadolinium enhancing lesions 51 AEGR 51 bronchial hyperresponsiveness 51 azilsartan medoxomil 51 TAXUS Express Stent 51 Study GL# 51 abacavir lamivudine 51 ruboxistaurin 51 pregabalin 51 neoadjuvant treatment 51 bortezomib 51 CLL SLL 51 neurologic progression 51 ribavirin therapy 51 glycosylated hemoglobin HbA1c 51 unstable angina UA 51 sargramostim 51 allogeneic SCT 51 moderate renal impairment 51 mcg doses 51 NPH insulin 51 adrenalectomy 51 SCH # 51 CorVue ™ 51 periprocedural 51 REYATAZ r arm 51 atherothrombotic events 51 LAB GHRH 51 statistical significance 51 CC genotype 51 TNF receptor 51 generalized edema 51 prior relapsers 51 Decitabine 51 stent binary restenosis 51 mg tid 51 non squamous histology 51 infusional 5-FU/LV 51 elevated ALT 51 thyroglobulin 51 relapsed SCLC 51 Natalizumab 51 SELENA SLEDAI 51 keloid scarring 51 gemcitabine carboplatin 51 BPH LUTS 51 oral vancomycin 51 baseline PASI 51 fraction LVEF 51 symptomatic VTE 51 LIALDA 51 % CI #.#-#.# [007] 51 Abbott HUMIRA 51 pT3 51 esophageal candidiasis 51 glycosylated hemoglobin 51 rimonabant #mg 51 Mean Symptom Complex 51 UACR 51 dobutamine 51 carboplatin paclitaxel 51 topotecan 51 statistical significance p 51 MEND CABG 51 elagolix 51 p = .# [002] 51 dose cytarabine 51 HER2 expression 51 neoadjuvant therapy 51 graft occlusion 51 azacitidine 51 HbA1C levels 51 FOLFIRINOX 51 TYGACIL 51 fibrinolytic therapy 51 huN# DM1 51 activated partial thromboplastin 51 rHuPH# 51 dabigatran etexilate 51 mL/min/#.# m2 51 RESIST studies 51 confidence interval CI 51 scores TNSS 51 nonsignificant 51 interferon beta therapy 51 dacarbazine 51 severe neutropenia 51 metastatic renal cell 51 highly emetogenic 51 #mg doses [002] 51 virologic 51 probable stent thrombosis 51 non inferiority 51 fingolimod 51 blood Phe 51 WOMAC pain 51 colectomy 51 intravaginal ejaculatory latency 51 ng dL 51 levosimendan 51 TNF inhibitor 51 Kaplan Meier estimate 51 antihypertensive therapy 51 QoL 51 intra arterial 51 BRIM2 51 standard chemotherapy regimen 51 HUMIRA achieved PASI 51 ibandronate 51 CHOP chemotherapy 51 FOSRENOL R 51 mg d 51 linaclotide treated 50 acute ischemic stroke 50 Rating Scale BPRS 50 Score IPSS 50 Dyloject TM 50 thymoma 50 aPTT 50 aMCI 50 subscore 50 angiographic outcomes 50 hours postdose 50 BROVANA 50 mCi kg 50 pulmonary exacerbations 50 Cimzia ® 50 apnea hypopnea index 50 dosing cohorts 50 factor Xa 50 NNT = 50 Cimzia TM 50 dyspnea 50 adefovir 50 serum triglycerides 50 Adalimumab 50 platelet aggregation 50 induction regimen 50 Betaferon ® 50 safinamide 50 bosentan 50 segment binary restenosis 50 TNF antagonists 50 Castration Resistant Prostate Cancer 50 retinal vein occlusion 50 opioid induced bowel dysfunction 50 esophageal erosions 50 PRECiSE 50 sirolimus eluting stent 50 divalproex sodium 50 serum testosterone 50 serum HCV RNA 50 nonsignificant difference 50 postintervention 50 imiquimod cream 50 gastrointestinal stromal tumors GIST 50 telbivudine 50 intima media thickness 50 ertapenem 50 Ophena TM 50 glycated hemoglobin HbA1c 50 Median survival 50 EGFR TKI 50 betamethasone dipropionate #.# 50 statistically significant improvement 50 colesevelam HCl 50 euthymic patients 50 ng dl 50 artery stenosis 50 relapsing remitting 50 HCV RESPOND 2 50 Lenalidomide 50 Amrubicin 50 iloprost 50 HCV Genotype 50 severe gastroparesis 50 TORISEL 50 non splenectomized 50 insulin detemir 50 metabolic parameters 50 estimated glomerular filtration 50 idraparinux 50 receiving VICTRELIS 50 underwent resection 50 intraocular inflammation 50 serologically active SLE 50 mcg mL 50 ejection fraction 50 AGILECT R 50 QTcF 50 teriparatide 50 DOXIL 50 EULAR 50 mycophenolate mofetil 50 vWF 50 virologic responses 50 imipenem 50 HER2 positive metastatic breast 50 LHRH antagonists 50 RAPAFLO 50 statistically significant reduction 50 mcg linaclotide 50 Targretin capsules 50 Ramipril 50 oral ridaforolimus 50 mutated KRAS 50 AUA Symptom Score 50 CombAT 50 imiquimod 50 Knodell necroinflammatory score 50 Mania Rating Scale 50 migalastat HCl 50 TLR antagonist 50 comparator PI r 50 MMSE scores 50 Zevalin R Ibritumomab 50 PROMACTA 50 splenectomized 50 FDG PET imaging 50 idursulfase 50 nab paclitaxel 50 hemodynamically significant 50 TNF Tumor Necrosis Factor 50 rotigotine 50 Postoperatively 50 olmesartan medoxomil hydrochlorothiazide 50 GLIADEL R Wafer 50 Octreolin 50 #.#g/day 50 Pain Rating Scale 50 lymphoma CTCL 50 QTc 50 bronchodilation 50 pancreatic carcinoma 50 crizotinib PF # 50 Zometa hazard 50 metformin monotherapy 50 ADAGIO study 50 preoperative PSA 50 iclaprim 50 administered subcutaneously 50 EBRT 50 hypercalcemia 50 TMC# r 50 Sprycel dasatinib 50 serum urate levels 50 sipuleucel T 50 imatinib therapy 50 olmesartan 50 dimebon 50 inhibitor RG# 50 rufinamide 50 PEG Intron 50 alemtuzumab treated 50 rilonacept 50 eplerenone 50 Nephrol Dial Transplant 50 sinus rhythm 50 TACE 50 CYT# QbG# 50 placebo PBO 50 Stage IIB 50 ABC/3TC 50 Scale PANSS 50 Celsentri Selzentry 50 Pharmacokinetics PK 50 TRANSFORMS 50 remission induction 50 QRS duration 50 MetS 50 intestinal mucosal 50 A1C levels 50 fluticasone 50 herpetic keratitis 50 anagrelide 50 advanced hepatocellular carcinoma 50 HAM D# 50 Ocular Surface Disease 50 zolmitriptan 50 airflow obstruction 50 zalutumumab 50 ritonavir boosted 50 disease progression TTP 50 hypomagnesemia 50 mg/# mg [001] 50 Meets Primary Endpoint 50 FOLFIRI 50 GOUT 50 underwent liver transplantation 50 asymptomatic carotid stenosis 50 antiretroviral naïve 50 CMV disease